Serum ACE2, Angiotensin II, and Aldosterone Levels Are Unchanged in Patients With COVID-19
© American Journal of Hypertension, Ltd 2020. All rights reserved. For Permissions, please email: journals.permissionsoup.com..
BACKGROUND: The role of the renin-angiotensin-aldosterone system (RAAS) in coronavirus disease 2019 (COVID-19) is controversially discussed. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters host cells by binding to angiotensin-converting enzyme 2 (ACE2) and activity of the RAAS may affect susceptibility to SARS-CoV-2 infection and outcome of patients with COVID-19.
METHODS: In this prospective single-center study, we determined the serum levels of ACE2, angiotensin II, and aldosterone in patients with COVID-19 compared with control patients presenting with similar symptoms in the emergency unit.
RESULTS: We analyzed serum samples from 24 SARS-CoV-2 positive and 61 SARS-CoV-2 negative patients. SARS-CoV-2 positive and control patients did not differ in baseline patients characteristics, symptoms, and clinical presentation. Mean serum concentrations of ACE2, angiotensin II, and aldosterone did not differ between the SARS-CoV-2 positive and the control group. In line with this, serum potassium as surrogate parameter for RAAS activity and blood pressure were similar in both groups.
CONCLUSIONS: In summary, we did not find evidence for altered RAAS activity including angiotensin II, aldosterone, or potassium levels, and blood pressure in patients with COVID-19.
CLINICAL TRIALS REGISTRATION: Trial Number DRKS00021206.
| Errataetall: |
CommentIn: Am J Hypertens. 2021 Apr 2;34(3):296-297. - PMID 33156903 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
American journal of hypertension - 34(2021), 3 vom: 02. Apr., Seite 278-281 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rieder, Marina [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.04.2021 Date Revised 22.04.2021 published: Print CommentIn: Am J Hypertens. 2021 Apr 2;34(3):296-297. - PMID 33156903 Citation Status MEDLINE |
|---|
| doi: |
10.1093/ajh/hpaa169 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316137782 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316137782 | ||
| 003 | DE-627 | ||
| 005 | 20231225160429.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ajh/hpaa169 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1053.xml |
| 035 | |a (DE-627)NLM316137782 | ||
| 035 | |a (NLM)33043967 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rieder, Marina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serum ACE2, Angiotensin II, and Aldosterone Levels Are Unchanged in Patients With COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.04.2021 | ||
| 500 | |a Date Revised 22.04.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Am J Hypertens. 2021 Apr 2;34(3):296-297. - PMID 33156903 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © American Journal of Hypertension, Ltd 2020. All rights reserved. For Permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: The role of the renin-angiotensin-aldosterone system (RAAS) in coronavirus disease 2019 (COVID-19) is controversially discussed. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters host cells by binding to angiotensin-converting enzyme 2 (ACE2) and activity of the RAAS may affect susceptibility to SARS-CoV-2 infection and outcome of patients with COVID-19 | ||
| 520 | |a METHODS: In this prospective single-center study, we determined the serum levels of ACE2, angiotensin II, and aldosterone in patients with COVID-19 compared with control patients presenting with similar symptoms in the emergency unit | ||
| 520 | |a RESULTS: We analyzed serum samples from 24 SARS-CoV-2 positive and 61 SARS-CoV-2 negative patients. SARS-CoV-2 positive and control patients did not differ in baseline patients characteristics, symptoms, and clinical presentation. Mean serum concentrations of ACE2, angiotensin II, and aldosterone did not differ between the SARS-CoV-2 positive and the control group. In line with this, serum potassium as surrogate parameter for RAAS activity and blood pressure were similar in both groups | ||
| 520 | |a CONCLUSIONS: In summary, we did not find evidence for altered RAAS activity including angiotensin II, aldosterone, or potassium levels, and blood pressure in patients with COVID-19 | ||
| 520 | |a CLINICAL TRIALS REGISTRATION: Trial Number DRKS00021206 | ||
| 650 | 4 | |a Clinical Study | |
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ACE2 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a aldosterone | |
| 650 | 4 | |a angiotensin II | |
| 650 | 4 | |a blood pressure | |
| 650 | 4 | |a hypertension | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Angiotensin II |2 NLM | |
| 650 | 7 | |a 11128-99-7 |2 NLM | |
| 650 | 7 | |a Aldosterone |2 NLM | |
| 650 | 7 | |a 4964P6T9RB |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 650 | 7 | |a Potassium |2 NLM | |
| 650 | 7 | |a RWP5GA015D |2 NLM | |
| 700 | 1 | |a Wirth, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Pollmeier, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Jeserich, Maren |e verfasserin |4 aut | |
| 700 | 1 | |a Goller, Isabella |e verfasserin |4 aut | |
| 700 | 1 | |a Baldus, Niklas |e verfasserin |4 aut | |
| 700 | 1 | |a Schmid, Bonaventura |e verfasserin |4 aut | |
| 700 | 1 | |a Busch, Hans-Joerg |e verfasserin |4 aut | |
| 700 | 1 | |a Hofmann, Maike |e verfasserin |4 aut | |
| 700 | 1 | |a Kern, Winfried |e verfasserin |4 aut | |
| 700 | 1 | |a Bode, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Duerschmied, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Lother, Achim |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of hypertension |d 1988 |g 34(2021), 3 vom: 02. Apr., Seite 278-281 |w (DE-627)NLM012611670 |x 1941-7225 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2021 |g number:3 |g day:02 |g month:04 |g pages:278-281 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ajh/hpaa169 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2021 |e 3 |b 02 |c 04 |h 278-281 | ||